Each tablet contains: Allopurinol 100 mg and 300 mg.
Allurase selectively inhibits action of xanthine oxidase, an essential enzyme responsible for synthesis of uric acid thus decreasing urate pool, resorbing tophaceous deposits and ultimately preventing hyperuricosuria.
Treatment of gout either primary or secondary to the hyperuricemia associated with blood dyscrasias and their therapy, primary or secondary uric acid nephropathy, with or without accompanying symptoms of gout; recurrent uric acid formation. Allurase is also used in prophylactic treatment to prevent tissue deposition, renal calculi, or uric acid nephropathy in patients with leukemias, lymphomas and malignancies who are receiving cancer chemotherapy with its resultant elevating effect on serum uric acid levels.
Adults: 100 to 200 mg daily in mild conditions.
300 to 600 mg daily in moderately severe conditions.
700 to 900 mg daily in severe conditions.
Children under 15 years: 100 to 400 mg daily.
Generally contraindicated in children except for those with hyperuricemia secondary to malignancy; in pregnant and lactating mothers and in patients with idiopathic hemochromatosis.
Patients who have developed a severe reaction should not be restarted with the drug. Periodic liver function tests should be performed particularly in patients with pre-existing hepatic and renal diseases.
M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.
Tab 100 mg x 100's. 300 mg x 50's.